No Data
Express News | Soligenix Shares Are Trading Higher After the Company Announced Interim Data From Its Investigator-initiated Study of HyBryte for Early-stage Cutaneous T-cell Lymphoma, Which Showed Over 70% of Patients Who Completed at Least 18 Weeks of Therapy...
Express News | Hybryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
Express News | EXCLUSIVE: Soligenix Tells Benzinga 'Patients Have Responded Positively to HyBryte Therapy, With Over 70% (5 of the 6 Subjects Who Have Completed at Least 18 Weeks of Therapy) Already Achieving "Treatment Success'
Express News | EXCLUSIVE: Soligenix Tells Benzinga 'Study Supported by $2.6 Million FDA Orphan Products Development Grant'
EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year
Soligenix Begins Patient Enrollment for Phase 3 Study of Drug Candidate for Cutaneous T-Cell Lymphoma
